Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides

Netherlands Heart Journal

Volumn 24, Issue 4, 2016, Pages 287-295

  Meijers, W C ^a   Hoekstra, T ^a   Jaarsma, T ^b   Van Veldhuisen, D J ^a   de Boer, R A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

B type natriuretic peptide; Biomarkers; Heart failure; Preserved ejection fraction; Quality of life; Symptoms

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TROPONIN I;

AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; COMORBIDITY; DEATH; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; QUALITY OF LIFE;

EID: 84963690291     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-016-0816-8     Document Type: Article

References (28)

1. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18–28.
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.
3. Jaarsma T, Halfens R, Abu-Saad HH, Dracup K, Stappers J, Ree J van. Quality of life in older patients with systolic and diastolic heart failure. Eur J Heart Fail. 1999;1:151–60.
4. Mentz RJ, Kelly JP, Lueder TG von, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281–93.
5. Brouwers FP, Boer RA de, Harst P. van der, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34:1424–31.
6. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.
7. Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.
8. Jaarsma T, Van Der Wal MH, Hogenhuis J, et al. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail. 2004;6:227–33.
9. Jaarsma T, Wal MH van der, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168:316–24.
10. Hoekstra T, Lesman-Leegte I, Veldhuisen DJ van, Sanderman R, Jaarsma T. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail. 2011;9:1013–5.
11. Meijers WC, Januzzi JL, deFilippi C, et al. Elevated plasma galectin- 3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 2014;167:853–60.
12. Jenkins LS, Brodsky M, Schron E, et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:112–20.
13. VanderZee KI, Sanderman R, Heyink JW, Haes H de. Psychometric qualities of the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health status. Int J Behav Med. 1996;3:104–22.
14. Yamamoto K, Sakata Y, Ohtani T, Takeda Y, Mano T. Heart failure with preserved ejection fraction. Circ J. 2009;73:404–10.
15. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.
16. Frankenstein L, Remppis A, Nelles M, et al. Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J. 2008;29:2634–40.
17. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005;112:2163–8.
18. Peacock WF 4th, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26.
19. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571–9.
20. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33:2001–6.
21. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600.
22. van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498–506.
23. Kang SH, Park JJ, Choi DJ, et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart. 2015;101:1881–8.
24. Meijers WC, de Boer RA, van Veldhuisen DJ, et al. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail. 2015;17:1271–82.
25. Brunner-La Rocca HP, Eurlings L, Richards AM, et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail. 2015;17:1252–61.
26. Edelmann F, Gelbrich G, Dungen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex- DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol. 2011;58:1780–91.
27. Lewis EF, Lamas GA, OʼMeara E, et al. Characterization of healthrelated quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83–91.
28. Caughey MC, Avery CL, Ni H, et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am J Cardiol. 2014;114:1850–4.